BioAtla and AI-driven partner GATC Health announced a $40 million special purpose vehicle transaction to advance ozuriftamab vedotin (Oz‑V), a CAB-ROR2 antibody‑drug conjugate, into a Phase 3 registrational trial for second‑line-or-later oropharyngeal squamous cell carcinoma (OPSCC). The SPV structures focused capital to support the registrational study design and execution. The deal blends a conditionally active biologic developer with an AI‑biotech partner — reflecting an industry pattern of coupling novel biologic platforms with data-driven development engines. The funding reduces near-term dilution for BioAtla and accelerates Oz‑V’s pathway toward a potential label in an underserved head-and-neck cancer population.